Biotech entity
Every one of those 1 sits in a single category, funding. Of the tracked stories, 1 of 1 also mention Astromech, the most common co-covered peer. We currently track 1 Biotech story that mention Breaking, all published on July 21, 2026.
Last mentioned: Jul 21, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, funding. Of the tracked stories, 1 of 1 also mention Astromech, the most common co-covered peer. We currently track 1 Biotech story that mention Breaking, all published on July 21, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Breaking. Shared-story counts are live from our verified record — not editorial picks.
Funding talks reported at $20B–$30B valuation
Axios and TechCrunch report Colossal is in discussions to raise new capital at a valuation between $20 billion and $30 billion.
Tasmanian devil cancer partnership launched
Colossal Foundation partners with University of Tasmania to combat contagious facial cancer in Tasmanian devils.
Artificial womb tech expected ready in 2027
CEO Ben Lamm tells Rolling Stone the technology could be spun off for human fertility applications.
Bluebuck antelope added as sixth target species
Colossal expands de-extinction pipeline to include bluebuck antelope.
Astromech spinout achieves $2B valuation
AI-driven biology predictive modeling company reaches unicorn status just months after launch.
Colossal valued at $10.2B after dire wolf project reveal
Investors justify valuation based on broad technology platform, not just de-extinction.
Colossal Biosciences is reportedly eyeing a valuation of $20 to $30 billion — more than double its 2025 mark — as it transitions from a de-extinction curiosity into a broad gene-editing and AI platform with multiple revenue streams, spinouts in plastics and fertility tech, and growing conservation contracts.
Source: TechCrunch · Marina Temkin (us)
Breaking is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
